Parcourir Revue médecine/sciences par auteur "Jordan, Bertrand"
Voici les éléments 1-20 de 167
-
ADN et portait-robot : où en est-on ?
Jordan, Bertrand (EDP Sciences, 2020)The prediction of a person’s aspect from analysis of an anonymous DNA sample has made significant progress in the last decade. Pigmentation (eyes, hair and, more recently, skin colour) can now be determined with good ... -
Les années 2000
Peschanski, Marc; Bergeron, Michel; Boué, André; Coppens, Yves; Changeux, Jean-Pierre; Corvol, Pierre; Lazar, Philippe; Kahn, Axel; Bichet, Daniel G.; Friedlander, Gérard; Epelbaum, Jacques; Kroemer, Guido; Chneiweiss, Hervé; Munnich, Arnold; Bouvier, Michel; Jordan, Bertrand; Frydman, René; Morange, Michel; Fougereau, Michel (Éditions EDK, Groupe EDP Sciences, 2015) -
Les années 2010
Bouvier, Michel; Chneiweiss, Hervé; Jordan, Bertrand; Lagrue, Gilbert; Ménard, Joël; Teillaud, Jean-Luc; Kroemer, Guido; Moulin, Anne-Marie; Flahault, Antoine; Lafanechère, Laurence; Maréchal, Éric; Guillemot, Jean-Claude; Gaille, Marie (Éditions EDK, Groupe EDP Sciences, 2015) -
Axel, médecine/sciences et les « Chroniques génomiques ». Une longue histoire…
Jordan, Bertrand (EDP Sciences, 2021) -
Bases alternatives et organismes synthétiques : Chroniques Génomiques
Jordan, Bertrand (EDP Sciences, 2018)Alternative bases that can fit into the DNA double helix have now been used in vivo to direct the synthesis of proteins incorporating unnatural amino acids. This bioengineering feat is significant at both the conceptual ... -
Bébés CRISPR : Anatomie d’une transgression
Jordan, Bertrand (EDP Sciences, 2019)Analysing the data recently presented by Jiankui He and assuming that it is authentic shows that the goal of abolishing the expression of CCR5 may have been reached for one of the resulting twins, although this remains to ... -
Bénéfice clinique et coût des traitements anticancéreux
Jordan, Bertrand (EDP Sciences, 2020)A detailed analysis of the clinical benefit for 47 approved cancer drugs, using two internationally recognized assessment systems, shows essentially no correlation between clinical benefit and weekly treatment costs. This ... -
Le business du clonage
Jordan, Bertrand (EDK, 2002) -
Cancer : Thérapies « complémentaires » et observance du traitement anti-tumoral font-elles bon ménage ?
Jordan, Bertrand (EDP Sciences, 2018)A recent paper shows that cancer patients using complementary therapies in addition to conventional treatment have distinctly worse outcomes. Analysis of the data shows that they are much more likely to refuse one component ... -
CCR5 et longévité : une rétraction
Jordan, Bertrand (EDP Sciences, 2019) -
Chacun sa séquence !
Jordan, Bertrand (EDK, 2009) -
Chroniques génomiques - 23andMe et le mal des transports
Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2016)A Genome Wide Association Study on propensity to motion sickness published by 23andMe gives interesting results, shows validity for self-reported phenotypic information and underlines the value of the model developed by ... -
Chroniques génomiques - 23andMe ou comment (très bien) valoriser ses clients
Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)The announcement of several deals between the DTC genetics firm 23andMe and Genentech, Pfizer and other corporations reveals the real business model of the company: selling access to sets of characterized patients for ... -
Chroniques génomiques - Actualités du séquençage d’ADN
Jordan, Bertrand (EDP Sciences, 2019)The planned acquisition of Pacific Biosciences by Illumina could signal a big change in the DNA sequencing landscape, and provides the incentive for an update on a field that still has a number of players and could be ... -
Chroniques génomiques - AlphaFold : un pas essentiel vers la fonction des protéines
Jordan, Bertrand (EDP Sciences, 2021) -
Chroniques génomiques - Balayage du génome et repérage des personnes à risque : Des GWAS aux GPS
Jordan, Bertrand (EDP Sciences, 2018)The accumulation of extensive repositories linking phenotypic and genetic information, together with new computation methods, makes it possible to derive polygenic scores for susceptibility to common diseases that turn out ... -
Chroniques génomiques - Biopsies liquides, une révolution en cancérologie ?
Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2015)The detection and analysis of circulating tumour DNA and/or circulating tumour cells in the blood of cancer patients open new possibilities for cancer characterisation and management. The approach has generated much ... -
Chroniques génomiques - Cancer : les trois époques de la médecine personnalisée :
Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2017)Since the completion of the first human DNA sequence, genomic approaches have penetrated into cancer research and therapy: first through expression profiling for diagnostic, prognostic and predictive purposes, then by ... -
Chroniques génomiques - Cancer :faut-il viser la lune ?
Jordan, Bertrand (Éditions EDK, Groupe EDP Sciences, 2016)The recently announced “Cancer moonshot” may be greeted with scepticism: the previous “War on cancer” (1971) was not very successful. However the current plan seems well targeted, with emphasis not only on research investment ... -
Chroniques génomiques - Cent ans après, le retour de la phagothérapie ?
Jordan, Bertrand (EDP Sciences, 2019)Bacteriophages were advocated as therapeutic agents more than a century ago, but the advent of antibiotics relegated them to a very minor role. Today, multi-drug resistant bacteria are a serious health problem, and phage ...